| Long-term accounts receivable, net | — | — | — | — | — | — | $2.1B | $2.5B |
| Noncontrolling interests in subsidiaries | $6M | $6M | $3M | $3M | $2M | $1M | $0 | -$1M |
| Aggregate Notional Principal Outstanding | — | — | $27B | — | — | — | $29.3B | — |
| Nonperforming Loans and Leases Percentage | — | — | $23B | — | — | — | $25.2B | — |
| Cumulative Cost Basis | — | — | $4.1B | — | — | — | $3.5B | — |
| Deferred Revenue Timing Percentage | — | — | 50.0% | — | — | — | 50.0% | — |
| Derivative Notional Amount | — | — | $27B | — | — | — | $29.3B | — |
| Fair Value Measurement Disclosure | — | — | $571M | — | — | — | $325M | — |
| Gross Assets/Liabilities | — | — | $571M | — | — | — | $325M | — |
| Guarantor Obligations - Maximum Exposure | — | — | $368M | — | — | — | $458M | — |
| Indemnification Liability Maximum Exposure | — | — | $368M | — | — | — | $458M | — |
| Line of Credit Maximum Borrowing Capacity | — | — | $14.6B | — | — | — | $15.8B | — |
| Line of Credit Remaining Borrowing Capacity | — | — | $9.9B | — | — | — | $9.7B | — |
| Operating Lease Income - 2023 (Lessor) | — | — | $317M | — | — | — | $397M | — |
| Operating Lease Income - 2024 (Lessor) | — | — | $317M | — | — | — | $397M | — |
| Total | — | — | $4.1B | — | — | — | $3.5B | — |
| Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 | — | — | $304M | — | — | — | $378M | — |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 | — | — | $301M | — | — | — | $383M | — |
| Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five | — | — | $1.8B | — | — | — | $1.5B | — |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five | — | — | $1.8B | — | — | — | $1.5B | — |
| Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10 | — | — | $102M | — | — | — | $202M | — |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10 | — | — | $102M | — | — | — | $202M | — |
| Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One | — | — | $1.3B | — | — | — | $744M | — |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One | — | — | $1.3B | — | — | — | $748M | — |
| Available for sale investments | — | — | $4B | — | — | — | $3.5B | — |
| Common Stock, Shares, Outstanding | — | — | $477.9M | — | — | — | $465.3M | — |
| Contract with Customer, Asset, after Allowance for Credit Loss | — | — | $238M | — | — | — | $297M | — |
| Contract with Customer, Liability | — | — | $2.7B | — | — | — | $4.7B | — |
| Non-current retainage balances | — | — | $640M | — | — | — | $1B | — |
| Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss | — | — | $75M | — | — | — | $26M | — |
| Less than 12 months | — | — | $875M | — | — | — | $177M | — |
| 12 months or more | — | — | $1.3B | — | — | — | $763M | — |
| Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss | — | — | $6M | — | — | — | $0 | — |
| Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss | — | — | $81M | — | — | — | $26M | — |
| Debt Securities, Available-for-Sale, Unrealized Loss Position | — | — | $2.2B | — | — | — | $940M | — |
| Deferred Tax Liabilities, Gross | — | — | $1.7B | — | — | — | $1.8B | — |
| Deferred income taxes | — | — | $432M | — | — | — | $494M | — |
| Deferred Tax Assets, Gross | — | — | $5.4B | — | — | — | $4.9B | — |
| Deferred Tax Assets, Net | — | — | $2.8B | — | — | — | $2.3B | — |
| Deferred Tax Assets, Net of Valuation Allowance | — | — | $3.2B | — | — | — | $2.8B | — |
| Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Postretirement Benefits | — | — | $560M | — | — | — | $425M | — |
| Deferred Tax Assets, Valuation Allowance | — | — | $874M | — | — | — | $840M | — |
| Deferred Tax Liabilities, Other | — | — | $454M | — | — | — | $429M | — |
| Defined Benefit Plan, Expected Gross Prescription Drug Subsidy Receipts | — | — | $46M | — | — | — | $42M | — |
| Derivative, gross, assets | — | — | $462M | — | — | — | $496M | — |
| Derivative Asset, Including Not Subject to Master Netting Arrangement, after Offset and Deduction | — | — | $276M | — | — | — | $336M | — |
| Derivatives, gross, liabilities | — | — | $571M | — | — | — | $325M | — |
| Derivative Liability, Including Not Subject to Master Netting Arrangement, after Offset and Deduction | — | — | $385M | — | — | — | $165M | — |
| Potential reduction in net position of total derivative liabilities | — | — | $186M | — | — | — | $160M | — |
| Notional | — | — | $27B | — | — | — | $29.3B | — |
| Unrecognized compensation cost related to non-vested awards | — | — | $148M | — | — | — | $209.1M | — |
| Finite-Lived Intangible Assets, Accumulated Amortization | — | — | $2.4B | — | — | — | $2.4B | — |
| 2028 | — | — | $96M | — | — | — | $35M | — |
| 2030 | — | — | $26M | — | — | — | $24M | — |
| 2031 | — | — | $23M | — | — | — | $21M | — |
| 2027 | — | — | $166M | — | — | — | $98M | — |
| 2029 | — | — | $33M | — | — | — | $27M | — |
| Finite Lived Intangible Assets Amortization Expense After Year Five | — | — | $55M | — | — | — | $36M | — |
| Gross Carrying Amount | — | — | $2.8B | — | — | — | $2.6B | — |
| Goodwill, Gross | — | — | $7.4B | — | — | — | $7.4B | — |
| Goodwill accumulated impairment losses | — | — | $2.1B | — | — | — | $2.1B | — |
| Value of financial guarantee (up to) | — | — | $368M | — | — | — | $458M | — |
| Lessee Operating Lease Liability Payments Due | — | — | $679M | — | — | — | $842M | — |
| Lessee Operating Lease Liability Undiscounted Excess Amount | — | — | $77M | — | — | — | $114M | — |
| Amount outstanding under the credit facility | — | — | $687M | — | — | — | $771M | — |
| Committed Revolving Credit Facilities | — | — | $14.6B | — | — | — | $15.8B | — |
| 2028 | — | — | $8.5B | — | — | — | $8.9B | — |
| 2029 | — | — | $7.8B | — | — | — | $7.7B | — |
| 2029 | — | — | $2.6B | — | — | — | $1.3B | — |
| 2030 | — | — | $214M | — | — | — | $3.1B | — |
| 2027 | — | — | $6.7B | — | — | — | $7.1B | — |
| Operating Lease Weighted Average Discount Rate Percent | — | — | $0 | — | — | — | $0 | — |
| Defined Benefit Plan, Expected Future Prescription Drug Subsidy Receipt, after Year Five | — | — | $19M | — | — | — | $17M | — |
| Defined Benefit Plan, Expected Future Prescription Drug Subsidy Receipt, Year One | — | — | $6M | — | — | — | $6M | — |
| Defined Benefit Plan, Expected Future Prescription Drug Subsidy Receipt, Year Five | — | — | $5M | — | — | — | $4M | — |
| Defined Benefit Plan, Expected Future Prescription Drug Subsidy Receipt, Year Four | — | — | $5M | — | — | — | $5M | — |
| Defined Benefit Plan, Expected Future Prescription Drug Subsidy Receipt, Year Three | — | — | $5M | — | — | — | $5M | — |
| Defined Benefit Plan, Expected Future Prescription Drug Subsidy Receipt, Year Two | — | — | $6M | — | — | — | $5M | — |
| Standard and Extended Product Warranty Accrual | — | — | $1.7B | — | — | — | $1.6B | — |
| Remaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied | — | — | $15.2B | — | — | — | $30.1B | — |
| Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number | — | — | $3.7M | — | — | — | $3M | — |
| Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price | — | — | $195.3 | — | — | — | $220.5 | — |
| Incentive stock program, shares reserved for future grants (in shares) | — | — | $40.9M | — | — | — | $39.3M | — |
| Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value | — | — | $625M | — | — | — | $1.1B | — |
| Shares reserved for awards to employees and outside directors (in shares) | — | — | $42.5M | — | — | — | $42.5M | — |
| Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable | — | — | $2.6M | — | — | — | $2.3M | — |
| Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value | — | — | $509M | — | — | — | $867M | — |
| Supplier finance program, obligation | — | — | $830M | — | — | — | $936M | — |
| Treasury stock, shares (in shares) | — | — | $337M | — | — | — | $349.6M | — |
| Unrecognized tax benefits | — | — | $1.3B | — | — | — | $1.3B | — |
| Amount that if recognized, would affect the effective tax rate or regulatory liability | — | — | $1.1B | — | — | — | $1.2B | — |
| Sublease Income - Thereafter | — | — | $37M | — | — | — | $80M | — |
